A team of scientists from the Cell Biology and Immunology group leads the charge in developing advanced in vitro models and nanoparticle tracking techniques. They designed and tested the nanoparticle and spearhead the communication and outreach efforts to ensure the science is accessible and meaningful to all involved.

Clinical researchers ensure that VIVID is not just scientifically rigorous but also patient-focused. They oversee the clinical phase of the study, coordinating recruitment, ethical oversight, and the actual imaging and surgical timeline. Their commitment ensures that the trial is designed with minimal burden on patients while maximising information gathered from each step.

An innovative SME based in Germany, contributes their deep expertise in nanoparticle formulation. Their team is responsible for producing and scaling the unique perfluorocarbon nanoparticles that allow both imaging and immune cell tracking—crucial for the safety and performance of the trial.

Our regulatory partner, guides VIVID through the complex landscape of approvals and compliance. With extensive experience in clinical trial strategy, documentation, and interactions with ethics committees and regulatory agencies, they help transform our research into a medically and legally sound study that meets European requirements.